Evidence map›Paper›PMID 41299631›Full record

ArticleJournal of nanobiotechnology2025

Sono-triggered endoplasmic reticulum-targeted ROS burst silencing CD300ld to alleviate polymorphonuclear myeloid-derived suppressor cells for breast cancer treatment.

Xuejun Chen, Shaoyue Li, Qing Lu, Yitong Li, Mingrui Zhu, Shen Zhang, Yan Fang, Congjian Wen, Daohui Yang, Peili Fan and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xuejun Chen *Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Shaoyue Li *Department of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
Qing Lu *Department of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Yitong LiDepartment of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
Mingrui ZhuDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Shen ZhangDepartment of Medical Ultrasound, Center of Minimally Invasive Treatment for Tumor, Shanghai Tenth People's Hospital, School of Medicine, Tongji University, Shanghai, 200072, P. R. China.
Yan FangDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Huashan Hospital, Fudan University, Shanghai, 200040 , P. R. China.
Congjian WenDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Daohui YangDepartment of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, Fujian Province, P. R. China.
Peili FanDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China. fan.peili@zs-hospital.sh.cn.
Huixiong XuDepartment of Ultrasound, Institute of Ultrasound in Medicine and Engineering, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China. xu.huixiong@zs-hospital.sh.cn.
Haohao YinDepartment of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, 361015, Fujian Province, P. R. China. yin.haohao@zs-hospital.sh.cn.

Funding

China Postdoctoral Science Foundation 2023TQ0073National Natural Science Foundation of China 82202173National Natural Science Foundation of China 82302206Natural Science Foundation of China 82430064Natural Science Foundation of Fujian Province 2024J011437Scientific Research and Development Fund of Zhongshan Hospital of Fudan University 2022ZSQD07Shanghai Sailing Program 23YF1441600Xiamen Healthcare Guidance Project 3502Z20244ZD1106
6 · The paper itself

Abstract

Immunogenic cell death (ICD) significantly boosts anti-tumor immunotherapy effectiveness; however, the recruitment of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), driven by factors such as adenosine accumulation and oxygen depletion during ICD, impairs the overall therapeutic outcome as well as facilitates tumor development and metastasis. Recent studies identify CD300ld as a key regulator of PMN-MDSCs recruitment, making it a promising immunotherapeutic target. Here, an innovative strategy is developed to eminently amplify ICD while alleviating PMN-MDSC infiltration upon ultrasound (US) stimulation. A modified generation 5 (G5) poly(amidoamine) dendrimer (G5PBA) was employed to encapsulate hematoporphyrin (GH)-a widely used organic sonosensitizer-and modified the complex with pardaxin peptides (Par) to achieve precise endoplasmic reticulum (ER) targeting, and adsorbed the negatively charged siCD300ld (PGH@siRNA). Under US irradiation, PGH@siRNA precisely accumulates at ER to induce localized reactive oxygen species (ROS) bursts, and effectively silence CD300ld, thereby amplifying endoplasmic reticulum stress (ERS)-mediated ICD and reducing PMN-MDSCs infiltration to reshape the tumor microenvironment. This systematic preclinical evaluations demonstrated enhanced immune activation, suppressed metastasis, and improved therapeutic outcomes. This study introduces a sono-responsive synergistic strategy integrating ER-targeted sonodynamic therapy with gene silencing, offering a novel paradigm for targeting PMN-MDSCs and enhancing triple-negative breast cancer (TNBC) immunotherapy.

Indexed as

Breast NeoplasmsEndoplasmic ReticulumMyeloid-Derived Suppressor CellsReactive Oxygen SpeciesAnimalsCell Line, TumorDendrimersEndoplasmic Reticulum StressFemaleHumansImmunotherapyMiceMice, Inbred BALB CRNA, Small InterferingDendrimersReactive Oxygen SpeciesRNA, Small InterferingCD300ld silencingEndoplasmic reticulum stressPolymorphonuclear myeloid-derived suppressor cellsSonodynamic therapyTriple-negative breast cancerTumor immune microenvironment

Identifiers

PMID41299631
PMCPMC12751942

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.